480 results on '"Snyder, David S."'
Search Results
102. Potent, Metabolically Stable Benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR Inhibitors for Polycystic Kidney Disease
103. NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia
104. Interaction between Cyclosporine and Warfarin
105. Final Report of a Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation
106. A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis
107. Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.
108. Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.
109. A Phase I Study of the HDAC Inhibitor LBH589 in Combination with Imatinib for Patients with CML in Cytogenetic Remission with Residual Disease Detectable by Q-PCR.
110. Effective Targeting of Quiescent CML Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate.
111. Chronic Myelogenous Leukemia
112. NCCN Task Force Report: Molecular Markers in Leukemias and Lymphomas
113. Ethical Issues in Hematopoietic Cell Transplantation
114. Improved Outcomes Using Tacrolimus/Sirolimus for graft Versus Host Disease prophylaxis with a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant for Myelofibrosis
115. Thrombotic Microangiopathy with Tacrolimus/Sirolimus-Based GVHD Prophylaxis Regimen in Patients Undergoing Hematopoietic Stem Cell Transplant from a Matched Unrelated Donor
116. Persistence of Leukemia Stem Cells in Chronic Myelogenous Leukemia Patients in Complete Cytogenetic Remission on Imatinib Treatment for 5 Years
117. Total Marrow Irradiation (TMI): A New Ablative Regimen as Part of Tandem (T) Autologous Peripheral Blood Progenitor Cell Transplant (AT) for Patients (pts) with Multiple Myeloma (MM).
118. Reduced Intensity (RI) Allogeneic Hematopoietic Cell Transplantation (HCT) Improves Outcomes for Older (≥ 60 Yrs) Patients (Pts) with Acute Myeloid Leukemia (AML).
119. Analysis of Predictive Power of Prednisone Dose at 3 Months of Treatment on CGVHD Prognosis.
120. Clinical and Pathologic Analysis of 16 Cases of Relapsed Chronic Myeloid Leukemia After Stem Cell Transplantation
121. Clinical and pathologic analysis of extramedullary tumors after hematopoietic stem cell transplantation.
122. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome–positive leukemia
123. Peripheral Hematopoietic Stem Cell Mobilization and Collection Efficacy Is Not an Independent Prognostic Factor for Autologous Stem Cell Transplantation.
124. Tacrolimus and Sirolimus as GVHD Prophylaxis for HLA-MRD Allogeneic HCT Conditioned with 3 Regimens: Toxicity and Efficacy in 70 Patients.
125. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia
126. Coexistence of Inversion 16 and the Philadelphia Chromosome in Acute and Chronic Myeloid Leukemias
127. Allogeneic Transplant with Standard Conditioning, Reduced Intensity, or Non-Myeloablative Conditioning Regimen for Multiple Myeloma (MM).
128. A Pilot Study Evaluating the Safety and Efficacy of Imatinib Given Early after Transplant for High-Risk Philadelphia Chromosome-Postive Leukemias.
129. A Retrospective Study of Patients Treated with Imatinib Mesylate Prior to Allogeneic Hematopoietic Stem Cell Transplant.
130. Matched Unrelated Donor Hematopoietic Cell Transplantation Following Reduced-Intensity Conditioning for Treatment of Myelofibrosis.
131. Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature
132. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: Benign course responsive to imatinib with an RT-PCR advisory
133. Ethical Issues in Hematopoietic Cell Transplantation
134. Specific Killing of Ph+Chronic Myeloid Leukemia Cells by a Lentiviral Vector-Delivered Anti-bcr/ablSmall Hairpin RNA
135. Langerhans Cell Histiocytosis.
136. Myeloperoxidase Immunoreactivity in Adult Acute Lymphoblastic Leukemia
137. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors
138. Inhibition of bcr-abl Oncogene Expression by Novel Deoxyribozymes (DNAzymes)
139. Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease
140. Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group
141. Allogeneic Bone Marrow Transplant in Pediatric Patients with High-Risk Hematopoietic Malignancies Early in the Course of Their Disease
142. Controlling Panel Noise and Vibration Using Non-Contacting Test Methodologies
143. Improving Vehicle Body Structure NVH - An Experimental Approach
144. PERSISTENCE OF bcr-abl GENE EXPRESSION FOLLOWING BONE MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
145. Allogeneic Hematopoietic Cell Transplantation following Reduced Intensity Conditioning for Treatment of Myelofibrosis
146. Treatment of Chronic Myelogenous Leukemia with Bone Marrow Transplantation
147. Peri-Transplant Administration of Ruxolitinib (Rux) in Patients with Myelofibrosis (MF) Is Safe and Effective. A Pilot Study
148. Outcomes of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Adults with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL)
149. INHIBITION OF HUMAN MONOCYTE ANTIGEN PRESENTATION, BUT NOT HLA-DR EXPRESSION, BY CYCLOSPORINE.
150. Human serum and plasma have different sources of epidermal growth factor.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.